PTC Therapeutics에 대한 매도 수량은 투자자에게 PTC Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

PTC Therapeutics (NASDAQ:PTCT) 주식, 공매도 수량 보고

PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics Inc

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Sector Perform and raises the price target from $32 to $34.

News

Price Target

Analyst Ratings

PTCT

RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $34

Biotech

General

PTC Therapeutics Announces FDA Acceptance For Filing Of NDA For Sepiapterin For Pediatric And Adult Phenylketonuria Patients

FDA Grants Fast Track Designation To PTC Therapeutics' PTC518 Program For Huntington's Disease, Highlighting Its Potential As A Disease-Modifying Therapy

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and maintains $64 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target

Baird analyst Joel Beatty initiates coverage on PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform rating and announces Price Target of $44.

Initiation

Baird Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces Price Target of $44

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $62 to $64.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $64

Barclays analyst Gena Wang maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and raises the price target from $25 to $31.

Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $31

PTC Updates Full Year 2024 Financial Guidance:&nbsp;
<ul>
<li>PTC anticipates total revenues for full year 2024 to be between $700 million and $750 million.</li>
<li>PTC anticipates GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $740 million and $835 million, including expected R&amp;D expense milestone payments of up to $65 million.</li>
<li>PTC anticipates Non-GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $660 million and $755 million, including expected R&amp;D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.</li>
<li>PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&amp;D operating expenses. As of June 30, 2024, $35 million in milestones have been achieved, of which $15 million has been recorded as R&amp;D operating expenses and $20 million as contingent consideration payable.</li>
</ul>

Guidance

PTC Sees FY24 Revenue $700M-$750M Vs $749M Estimate

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.19) by 8.4 percent. The company reported quarterly sales of $186.704 million which beat the analyst consensus estimate of $185.319 million by 0.75 percent. This is a 12.68 percent decrease over sales of $213.808 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

PTC Therapeutics Q2 2024 GAAP EPS $(1.29) Misses $(1.19) Estimate, Sales $186.704M Beat $185.319M Estimate

PTC Therapeutics Submits Sepiapterin NDA To FDA For Treatment Of Pediatric And Adult Phenylketonuria (PKU) Patients

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and maintains $62 price target.

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $62 Price Target

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and raises the price target from $30 to $32.

Morgan Stanley Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $32

WIIM

PTC Therapeutics shares are trading higher following a report suggesting that the company requested a re-examination of the EMA's June 2024 opinion.

Global

EMA Says Company For Translarna Has Requested A Re-Examination Of EMA's June 2024 Opinion

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $52 to $62.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $62

PTC Therapeutics shares are trading lower after the CHMP issued a negative opinion on Translarna following the European Commission's request for review.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.2% on Friday.
Shares of NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) fell sharply in today's pre-market trading following fourth-quarter earnings and <a href="https://www.benzinga.com/news/earnings/24/06/39536852/nike-q4-earnings-highlights-revenue-miss-eps-beat-taking-our-near-term-challenges-head-on">soft FY25 guidance.</a>
Analysts at Stifel and Morgan Stanley downgraded the stock following the report.
NIKE shares dipped 15.6% to $79.42 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Accolade, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) shares tumbled 32.1% to $4.34 in pre-market trading after the company reported first-quarter financial results and issued worse-than-expected FY25 revenue guidance. Also, Needham maintained a Buy rating on the stock but lowered its price target from $13 to $8.</li>
<li>PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) shares slipped 13.5% to $30.00 in pre-market trading after the company said CHMP has issued negative opinion on renewal of conditional marketing authorization of Translarna (Ataluren) for the treatment of nmDMD.</li>
<li>Kura Sushi USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) shares declined 12.4% to $72.00 in pre-market trading after the company issued soft guidance.</li>
<li>Rocket Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) shares fell 12.4% to $18.75 in pre-market trading. The company announced the FDA issued a Complete Response Letter for the License Application For KRESLADI and requested limited additional Chemistry Manufacturing and Controls information to complete its review.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) fell 7.7% to $0.7613 in pre-market trading after the company published full year 2023 results.</li>
<li>Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) shares fell 5.3% to $24.16 in pre-market trading.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) shares declined 4.1% to $39.84 in pre-market trading. Apellis plans to seek re-examination following negative CHMP opinion for pegcetacoplan for geographic atrophy (GA) in the EU.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying">IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying</a> 
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACCD

APLS

KRUS

PSNY

RCKT

Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session

PTC Therapeutics Says CHMP Has Issued Negative Opinion On Renewal Of Conditional Marketing Authorization Of Translarna (Ataluren) For The Treatment Of nmDMD; Opinion Follows Return Of Previously Issued Negative Opinion By European Commission For Re-review

Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of $32.00. T...

Morgan Stanley Keeps Their Hold Rating on PTC Therapeutics (PTCT)

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

In a report released yesterday, Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report), with a...

PTC Therapeutics: Balancing Strong FY24 Guidance Against Regulatory Uncertainties

PTC Therapeutics rises as UBS restarts coverage with buy rating

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price target of $...

Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

PTC Therapeutics Huntington's disease candidate nabs FDA Fast Track status

Robert W. Baird analyst Joel Beatty has maintained their bullish stance on PTCT stock, giving a Buy rating on September 16. Joel Beatty has given h...

Positive Outlook on PTC Therapeutics: Buy Rating Backed by Fast Track Designation and Promising Clinical Trials

PTC Therapeutics brain disorder therapy granted FDA review

William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on September 26. Sami Corwin has given his...

Comments

PTC Therapeutics

매도 수량

PTC Therapeutics (NASDAQ:PTCT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌